Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?
Summit is expanding ivonescimab beyond lung cancer into colorectal, bladder, kidney and other cancers, backed by promising early data and collaboration deals.
SMMT - Summit Therapeutics Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$29.33
DETAILS
HIGH:
$41.00
LOW:
$16.00
MEDIAN:
$30.00
CONSENSUS:
$29.33
UPSIDE:
85.28%
Stock News
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Becomes the 7th International Registrational Clinical Trial for Ivonescimab Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its global partner for ivonescimab, has entered into a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab in a registration-enabling Phase II/III study in biliary tract cancer (BTC). The new study, EA2251 (NCT07765433), is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab plus chemotherapy in the first-line treatment of patients with advanced BTC.
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in a registration-enabling Phase II/III study in biliary tract cancer (BTC). The new study, EA2251 (NCT07765433), is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab pl.
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in previously untreated advanced clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. The study (SMT112-216 / AK112-216 / NCT07877194) is being conducted in collaboration with Summit's partner, Akeso Inc. SMT.
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The e
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody. Pursuant to the terms of the Securities Purchase Agreement entered into by Summit and AstraZeneca, AstraZeneca purchased an aggregate of approxi.
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE:
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), across multiple solid tumor settings, intending to include breast and lung cancer. The companies i.
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (Nasdaq: SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer (TNBC). Datroway is a specifically engineered TROP2 directed DXd antibo.
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up – What’s Next?
Summit Therapeutics PLC (NASDAQ: SMMT - Get Free Report)'s stock price gapped up prior to trading on Tuesday. The stock had previously closed at $15.48, but opened at $18.91. Summit Therapeutics shares last traded at $16.3970, with a volume of 10,558,930 shares traded. Key Summit Therapeutics News Here are the key news stories impacting Summit Therapeutics
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant read ivonescimab correctly.
Summit Shares Jump on $2B Strategic Investment From AstraZeneca
SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.
Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment
Summit Therapeutics (SMMT), which holds rights to the cancer drug ivonescimab in major markets outside China, rose 16.99% in premarket after AstraZeneca (AZN) a
AstraZeneca Invests in Summit Therapeutics after Year of Speculation
AstraZeneca Plc (NYSE:AZN) on Tuesday agreed to invest $2 billion in newly issued equity in Summit Therapeutics Inc. (NASDAQ:SMMT) to accelerate the development of ivonescimab in combination with antibody-drug conjugates (ADCs) across tumor types.
Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals
Summit Therapeutics shares surged more than 20% in pre-market trading on Tuesday after AstraZeneca agreed to invest $2 billion in the company and collaborate on a series of clinical studies involving their cancer treatments. The deal, announced late Monday, sent UK-listed shares of AstraZeneca 1.9% higher to a two-month high.
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, will invest $2 billion in Summit Therapeutics Inc. as part of a wider cancer drug collaboration.
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
Summit shares surged in after-hours trading following the news of AstraZeneca's investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up
Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments together.
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company's progress towards achieving its goal of making a significant difference in the lives of patients with cancer. Specifically, Summit has established agreements with AstraZeneca (LSE/STO/NYSE: AZN) for a strategic equity investment in Summit and a clinical collaboration focused on ivonescimab and sonesitatug vedotin (sone-ve). Moreover, Summit and AstraZeneca intend to evaluat.
Price Targets
Summit Therapeutics price target raised to $20 from $18 at Barclays
$20.00
(was $16.91)
Barclays
Goldman Sachs Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
$41.00
(was $15.48)
Satoru Ogawa
·
Goldman Sachs
Summit Therapeutics plc (SMMT) PT Raised to $30 at Jefferies
$30.00
(was $15.48)
Faisal Khurshid
·
Jefferies
Summit Therapeutics upgraded to Buy from Hold at Jefferies
$25.00
(was $17.28)
Faisal Khurshid
·
Summit Redstone Partners
UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
$33.00
(was $17.27)
David Dai
·
UBS
Bernstein SocGen Group Upgrades Summit Therapeutics plc (SMMT) to Market Perform
$11.90
(was $12.73)
Jeffrey Walch
·
Summit Redstone Partners
Summit Therapeutics price target lowered to $15 from $17 at Jefferies
$15.00
(was $13.68)
Jefferies
Summit Therapeutics price target lowered to $38 from $45 at Stifel
$38.00
(was $14.98)
Dara Azar
·
Stifel Nicolaus
Summit Therapeutics price target lowered to $38 from $40 at Guggenheim
$38.00
(was $14.98)
Brad Canino
·
Guggenheim
Summit Therapeutics price target lowered to $23 from $30 at H.C. Wainwright
$23.00
(was $16.11)
H.C. Wainwright
Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler
$16.00
(was $21.46)
Piper Sandler
Summit Therapeutics price target lowered to $30 from $40 at H.C. Wainwright
$30.00
(was $16.09)
H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
$40.00
(was $16.89)
Piper Sandler
Barclays Upgrades Summit Therapeutics plc (SMMT) to Equalweight
$18.00
(was $17.23)
Etzer Darout
·
Summit Redstone Partners
Summit Therapeutics plc (SMMT) PT Lowered to $40 at H.C. Wainwright
$40.00
(was $20.04)
H.C. Wainwright
Summit Therapeutics price target raised to $16 from $13 at Barclays
$16.00
(was $20.04)
Barclays
Summit Therapeutics initiated with an Underweight at Barclays
$13.00
(was $18.12)
Summit Redstone Partners
Piper starts Summit Therapeutics with Neutral on high expectations
$21.00
(was $25.71)
Kelsey Goodwin
·
Summit Redstone Partners
Summit Therapeutics selloff Friday on data overdone, says H.C. Wainwright
$44.00
(was $24.11)
H.C. Wainwright
Wells says Summit, Akeso data 'not the bull case,' but not 'bear case either'
$30.00
(was $23.47)
Wells Fargo